U.S. Unveils Phased Tariff Plan on Generic Drug Imports, Threatening India’s $9.7B Market

A proposed two-year grace period gives foreign drugmakers until August 2028 to shift production to the United States before steep import duties take effect.

WASHINGTON / NEW DELHI — The U.S. administration has announced a structured tariff policy targeting imported generic pharmaceuticals. Under the proposal, imported generic medicines will remain duty-free until August 1, 2028, after which they will face a 100% tariff for one year, escalating to a 200% tariff from August 2029 onward unless manufacturing is relocated to the United States.

The policy represents a major push to reshore pharmaceutical manufacturing to American soil. India—often termed the “pharmacy of the world”—faces the largest single-country exposure due to its dominant role in supplying affordable generic prescription drugs to American consumers.

Also Read | Akhilesh Yadav Clashes with Chair in Lok Sabha, Alleging Partiality in NEET Paper Leak Discussions

1. Timeline of Proposed Tariff Implementation

The policy sets a multi-stage transition roadmap intended to push global drugmakers toward domestic U.S. facility expansion:

📅 Proposed U.S. Generic Drug Tariff Roadmap:
 🟢 Aug 1, 2026 – July 31, 2028 ➔ 0% Tariff (2-Year Transition Window)
 🟡 Aug 1, 2028 – July 31, 2029 ➔ 100% Tariff on Imported Generics
 🔴 August 1, 2029 Onward       ➔ 200% Tariff on Imported Generics

This measure follows earlier trade actions targeting branded and patented pharmaceuticals, effectively bringing virtually all finished drug imports into the broader U.S. manufacturing reshoring strategy.

2. India’s High Exposure & Market Economics

India exported approximately $25.8 billion in pharmaceutical products worldwide in 2025. Of that total, $9.7 billion (37.7%) was directed to the United States, making it the Indian pharmaceutical industry’s single largest destination.

📊 India's Generic Supply to the U.S. Market:
 💊 Prescription Share ➔ ~47% of all generic prescriptions filled in U.S. pharmacies.
 💵 Import Value Share ➔ ~30% of total U.S. generic import value (due to low unit costs).
 🏥 Consumer Savings   ➔ Saved the U.S. healthcare system over $1 trillion in the past decade.

Top 10 Destinations for Indian Pharmaceutical Exports (CY2025)

Also Read | Akhilesh Yadav Clashes with Chair in Lok Sabha, Alleging Partiality in NEET Paper Leak Discussions